Mapping prescription drug monitoring program data to self-report measures of non-medical prescription opioid use in community pharmacy settings.
Community pharmacy
Non-medical prescription opioid use
Opioids
Prescription opioids
Screening
Substance abuse
Journal
Research in social & administrative pharmacy : RSAP
ISSN: 1934-8150
Titre abrégé: Res Social Adm Pharm
Pays: United States
ID NLM: 101231974
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
10
10
2022
revised:
12
04
2023
accepted:
21
04
2023
pmc-release:
01
08
2024
medline:
31
7
2023
pubmed:
5
5
2023
entrez:
4
5
2023
Statut:
ppublish
Résumé
Community pharmacists are well-positioned to identify patients engaged in non-medical prescription opioid use (NMPOU) through Prescription Drug Monitoring Program (PDMP) databases. Integrating patient-reported outcomes with PDMP data may improve the interpretability of PDMP information to support clinical decision-making. This study linked patient-reported clinical measures of substance use with PDMP data to examine relationships between average daily opioid dose in morphine milligram equivalents (MME) and visits to multiple pharmacies/prescribers with self-reported NMPOU. Data from a cross-sectional health assessment given to patients aged ≥18 years filling opioid prescriptions were linked to PDMP records. NMPOU in the past three months was assessed on a continuous scale (range 0-39) using an adapted version of the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST). PDMP measures included average daily MME and number of distinct pharmacies/prescribers visited in the past 180 days. Univariable and multivariable zero-inflated negative binomial models estimated associations between PDMP measures and any NMPOU and severity of use. The sample included 1421 participants. In multivariable models adjusted for sociodemographic, mental health, and physical health characteristics, any NMPOU was associated with higher average daily MME (adjusted OR = 1.22, 95% CI = 1.05-1.39) and number of distinct prescribers visited (adjusted OR = 1.15, 95% CI = 1.01-1.30). Higher average daily MME (adjusted mean ratio (MR) = 1.12, 95% CI = 1.08-1.15), number of distinct pharmacies visited (adjusted MR = 1.11, 95% CI = 1.04-1.18), and number of distinct prescribers visited (adjusted MR = 1.07, 95% CI = 1.02-1.11) were associated with increased NMPOU severity. We observed significant, positive associations between average daily MME and visits to multiple pharmacies/prescribers with any NMPOU and severity of use. This study demonstrates self-report clinical measures of substance use can be cross-walked to PDMP data and translated into clinically interpretable information.
Sections du résumé
BACKGROUND
Community pharmacists are well-positioned to identify patients engaged in non-medical prescription opioid use (NMPOU) through Prescription Drug Monitoring Program (PDMP) databases. Integrating patient-reported outcomes with PDMP data may improve the interpretability of PDMP information to support clinical decision-making.
OBJECTIVE
This study linked patient-reported clinical measures of substance use with PDMP data to examine relationships between average daily opioid dose in morphine milligram equivalents (MME) and visits to multiple pharmacies/prescribers with self-reported NMPOU.
METHODS
Data from a cross-sectional health assessment given to patients aged ≥18 years filling opioid prescriptions were linked to PDMP records. NMPOU in the past three months was assessed on a continuous scale (range 0-39) using an adapted version of the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST). PDMP measures included average daily MME and number of distinct pharmacies/prescribers visited in the past 180 days. Univariable and multivariable zero-inflated negative binomial models estimated associations between PDMP measures and any NMPOU and severity of use.
RESULTS
The sample included 1421 participants. In multivariable models adjusted for sociodemographic, mental health, and physical health characteristics, any NMPOU was associated with higher average daily MME (adjusted OR = 1.22, 95% CI = 1.05-1.39) and number of distinct prescribers visited (adjusted OR = 1.15, 95% CI = 1.01-1.30). Higher average daily MME (adjusted mean ratio (MR) = 1.12, 95% CI = 1.08-1.15), number of distinct pharmacies visited (adjusted MR = 1.11, 95% CI = 1.04-1.18), and number of distinct prescribers visited (adjusted MR = 1.07, 95% CI = 1.02-1.11) were associated with increased NMPOU severity.
CONCLUSIONS
We observed significant, positive associations between average daily MME and visits to multiple pharmacies/prescribers with any NMPOU and severity of use. This study demonstrates self-report clinical measures of substance use can be cross-walked to PDMP data and translated into clinically interpretable information.
Identifiants
pubmed: 37142474
pii: S1551-7411(23)00236-X
doi: 10.1016/j.sapharm.2023.04.121
pmc: PMC10523937
mid: NIHMS1898886
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
MME
78185-58-7
Banques de données
ClinicalTrials.gov
['NCT03936985']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1171-1177Subventions
Organisme : NIDA NIH HHS
ID : UG1 DA013732
Pays : United States
Organisme : NIDA NIH HHS
ID : UG1 DA049444
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Références
Pain. 2015 Jul;156(7):1208-1214
pubmed: 25760471
BMJ. 2014 Feb 19;348:g1393
pubmed: 24553363
Clin J Pain. 2014 Jul;30(7):557-64
pubmed: 24281273
JAMA. 2011 Apr 6;305(13):1315-21
pubmed: 21467284
Med Care. 2012 Jun;50(6):494-500
pubmed: 22410408
Med Care. 2003 Nov;41(11):1284-92
pubmed: 14583691
J Am Pharm Assoc (2003). 2020 Jan - Feb;60(1):57-65
pubmed: 31753615
Medicine (Baltimore). 2019 May;98(20):e15425
pubmed: 31096439
BMJ. 2021 Nov 24;375:n2893
pubmed: 34819305
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042
J Addict Med. 2022 May-Jun 01;16(3):e171-e176
pubmed: 34417413
Pain Med. 2016 Jan;17(1):85-98
pubmed: 26333030
JAMA Intern Med. 2014 May;174(5):796-801
pubmed: 24589873
Yale J Biol Med. 2015 Sep 03;88(3):227-33
pubmed: 26339205
Ann Intern Med. 2011 Sep 6;155(5):325-8
pubmed: 21893626
Res Social Adm Pharm. 2016 May-Jun;12(3):509-14
pubmed: 26329535
Drug Alcohol Depend. 2021 Nov 1;228:109067
pubmed: 34610516
Ann Intern Med. 2010 Jan 19;152(2):85-92
pubmed: 20083827
Acad Emerg Med. 2018 May;25(5):508-516
pubmed: 29165853
Br J Math Stat Psychol. 2012 Feb;65(1):163-80
pubmed: 21950803
Res Social Adm Pharm. 2019 Jun;15(6):754-760
pubmed: 30243575
Addiction. 2016 Feb;111(2):233-44
pubmed: 26360315
Drug Alcohol Depend. 2021 Feb 1;219:108460
pubmed: 33387937
JAMA Netw Open. 2020 Sep 1;3(9):e2013431
pubmed: 32945874
Addiction. 2002 Sep;97(9):1183-94
pubmed: 12199834
Drug Alcohol Depend. 2019 Aug 1;201:260-265
pubmed: 31276986
Am J Drug Alcohol Abuse. 2011 Sep;37(5):376-82
pubmed: 21854280
Clin J Pain. 2004 Sep-Oct;20(5):309-18
pubmed: 15322437